STOCK TITAN

Rallybio $13.90 payout payments expected Nov. 30

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
425

Rhea-AI Filing Summary

Rallybio Corp. (RLYB) anticipates that its merger with Avenzo Therapeutics will close after trading on November 20, 2026, subject to satisfaction or waiver of outstanding closing conditions; Nasdaq approved listing Rallybio common stock on the Nasdaq Capital Market in connection with the merger. The previously announced $13.90-per-share cash distribution remains payable to stockholders and pre-funded warrant holders of record November 5, with entitlements affected by trades during Nasdaq’s due bill period.

The due bill period runs from November 5 through the close of trading on November 20: buyers during that period are entitled to the distribution and sellers are not, even if trades settle later. The transfer agent is expected to begin payments November 30, after the distribution amount is deposited November 19. Contingent value rights are expected to be distributed November 23. The reverse stock split is expected to take effect at 4:01 p.m. Eastern Time on November 20, without changing the distribution’s timing or amount.

Cash distribution $13.90 per share Special cash distribution payable to holders of record November 5, 2026, subject to due bill procedures.
Merger expected closing date November 20, 2026 Expected following the close of trading, subject to satisfaction or waiver of outstanding closing conditions.
Distribution record date November 5, 2026 Record date for the cash distribution and contingent value rights, subject to the due bill procedures for the cash distribution.
Due bill period end November 20, 2026 The due bill period runs through the close of trading.
Distribution deposit date November 19, 2026 The cash distribution amount is expected to be deposited with the transfer agent.
Distribution payment date November 30, 2026 The transfer agent is expected to commence distribution.
Contingent value rights distribution date November 23, 2026 Expected distribution date for holders of record November 5, one business day following the expected merger closing.
Reverse stock split effective time 4:01 p.m. Eastern Time on November 20, 2026 The reverse stock split is expected to take effect; the company said it will not affect the cash distribution’s timing or amount.
due bills technical
"common stock will trade with due bills from the Distribution Record Date"
Due bills are short-term promises to pay for goods or services received earlier but not yet paid for. They act like an IOU, indicating that the buyer owes money to the seller. For investors, due bills matter because they can affect the timing of payments and the true value of a transaction, impacting financial clarity and decision-making.
pre-funded warrants financial
"stockholders and pre-funded warrant holders of record"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
contingent value rights financial
"distribution of contingent value rights to holders of record"
Contingent value rights are special financial instruments that give their holder the potential to receive additional payments if certain future events or conditions happen, such as the achievement of specific business milestones. They are like a promise of extra rewards that depend on how well a project or company performs later on. Investors care about them because they offer a chance for extra gains but also carry uncertainty, as the extra payments are not guaranteed.
In the Money Parent Options financial
"and In the Money Parent Options as of the Distribution Record Date"
ex-dividend date financial
"the November 23, 2026 expected ex-dividend date"
The ex-dividend date is the date when a stock starts trading without the value of its next dividend payment included. If you buy the stock on or after this date, you won't receive that upcoming dividend; only those who owned the stock before this date are entitled to it. It matters to investors because it determines who is eligible to receive the dividend and can influence the stock’s price around that time.
reverse stock split financial
"reverse stock split of the Company’s outstanding shares of common stock"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Effective Date November 20, 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is Rallybio’s cash distribution and when is it expected to be paid?

Rallybio’s cash distribution is $13.90 per share, and the transfer agent is expected to begin distributing it on November 30, 2026. The distribution amount is expected to be deposited with the transfer agent on November 19. It is payable to stockholders and pre-funded warrant holders of record November 5, subject to the due bill procedures.

Who receives Rallybio’s cash distribution during the due bill period?

Buyers of Rallybio common stock during the due bill period are entitled to the cash distribution, while sellers are not, even if the trade settles after the period. The period runs from the November 5, 2026 record date through the close of trading on November 20.

When is Rallybio’s merger with Avenzo expected to close?

Rallybio anticipates the merger will close following the close of trading on November 20, 2026, subject to satisfaction or waiver of outstanding closing conditions. Nasdaq approved listing Rallybio common stock on the Nasdaq Capital Market in connection with the merger.

When are Rallybio contingent value rights expected to be distributed?

The contingent value rights are expected to be distributed on November 23, 2026 to holders of record as of November 5. Eligible holders include holders of common stock, pre-funded warrants, restricted stock units and In the Money Parent Options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2026

 

 

RALLYBIO CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-40693   85-1083789

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

PO Box No. 325  
East Berlin, Connecticut   06023
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: 203 859-3820

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☒

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   RLYB   NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 8.01 Other Events.

Rallybio Corporation (the “Company”) announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated as of May 31, 2026, by and among the Company, Avenzo Therapeutics, Inc. and Farmington Merger Sub, Inc., will close following the close of trading on November 20, 2026. The Company received approval from the Listing Qualifications department of The Nasdaq Stock Market to list its common stock on the Nasdaq Capital Market in connection with the Merger.

The Company also announced updates about its previously announced special cash distribution of $13.90 per share (the “Cash Distribution”). The Cash Distribution will continue to be payable in cash to stockholders and pre-funded warrant holders of record as of November 5, 2026 (the “Distribution Record Date”), subject to the Nasdaq due bill procedures described below, then based on their holdings as of the Distribution Record Date and during the Due Bill Period (as defined below). The actual distribution of the amount of the Cash Distribution will be deposited with the Company’s transfer agent on November 19, 2026 and the Company’s transfer agent is expected to commence distribution of the Cash Distribution on November 30, 2026 (the “Distribution Payment Date”) to stockholders and pre-funded warrant holders as of the Distribution Record Date and during the Due Bill Period, with payments expected to be received by such stockholders and warrant holders within a few days following the Distribution Payment Date.

As previously described, because the Cash Distribution per share exceeds 25% of the Company’s stock price on the declaration date, Nasdaq has advised the Company that its common stock will trade with due bills from the Distribution Record Date through the closing of trading on November 20, 2026 (the “Due Bill Period”), which is the last day of trading before the November 23, 2026 expected ex-dividend date for the Cash Distribution. Due bills obligate sellers of the Company’s common stock to deliver the Cash Distribution to the buyer of such common stock during the Due Bill Period. This means that persons who purchase the Company’s common stock during the Due Bill Period (even if the trade will settle after the Due Bill Period) are entitled to receive the Cash Distribution, and persons who sell the stock during the Due Bill Period (even if the trade will settle after the Due Bill Period) are not entitled to the Cash Distribution. Accordingly, if an investor wishes to receive the Cash Distribution, the investor will need to hold the securities through and including the closing of trading on November 20, 2026. The due bill obligations are settled customarily between the brokers representing the buyers and sellers of the stock. Buyers and sellers of the Company’s common stock should consult with their broker before trading to ensure they understand the effect of Nasdaq’s due bill procedures. The Company has no obligations for either the amount of the due bill or the processing of the due bill. The timing and amount of the Cash Distribution will not be impacted by the reverse stock split of the Company’s outstanding shares of common stock that was previously announced by the Company and expected to take effect at 4:01 p.m. Eastern Time on November 20, 2026.

In addition, the distribution of contingent value rights to holders of record of the Company’s common stock, pre-funded warrants, restricted stock units and In the Money Parent Options (as defined in the Merger Agreement) as of the Distribution Record Date is expected to occur on November 23, 2026, one business day following the closing of the transactions contemplated by the Merger Agreement.

Forward-Looking Statements

This Current Report on Form 8-K and the exhibits filed or furnished herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding the implementation and expected timing of the reverse stock split; the expected distribution of the Cash Distribution; the expected commencement of trading on a split-adjusted basis; the anticipated completion and timing of the Merger; the procedures for the Due Bill Period; and Avenzo’s and the Company’s plans to develop and commercialize therapies and the potential of their product candidates. The words “may,” “believes,” “expects,” “anticipates,” “intends,” “plans,” “forecasts,” “estimates,” “will,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These statements are based on management’s current expectations, estimates, beliefs and assumptions and are subject to risks and uncertainties that could cause actual results or the timing of events to differ materially from those expressed or implied.

These risks and uncertainties include, among others, the risk that the Merger will be delayed or will not be completed because closing conditions are not satisfied or waived, including conditions related to Nasdaq listing approvals; the occurrence of events or circumstances that could give rise to termination of the Merger Agreement; delays in implementing the reverse stock split or commencing split-adjusted trading; the risk that the reverse stock split will not result in a sustained increase in the trading price of the common stock or ensure compliance with Nasdaq listing requirements; risks associated with the development and commercialization of product candidates;

 


and the other risks described under “Risk Factors” in the Proxy Statement/Prospectus, the Company’s most recent Annual Report on Form 10-K and its subsequent filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on these forward-looking statements. These statements speak only as of the date of the communication in which they appear, and the Company undertakes no obligation to update or revise any forward-looking statement, except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

No Offer or Solicitation

This Current Report on Form 8-K and the exhibits filed or furnished herewith do not constitute an offer to sell or the solicitation of an offer to buy any securities. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended, and otherwise in accordance with applicable law.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

      RALLYBIO CORPORATION
Date: November 12, 2026     By:  

/s/ Jonathan I. Lieber

     

Jonathan I. Lieber

Chief Financial Officer

Keep reading